# Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 27.4 | 65.7 | (38.9-103.8) |  | Male | 27 | 17.7 | 152.8 | (100.7-222.4) |
| Female | 11 | 10.0 | 109.6 | (54.6-196.1) |  | Female | 14 | 13.7 | 102.1 | (55.8-171.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.1 | 118.0 | (43.1-256.8) |  | Male | 6 | 5.2 | 115.6 | (42.2-251.5) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 5 | 4.2 | 118.0 | (38.0-275.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 11 | 15.7 | 70.3 | (35.0-125.8) |
| Female | 133 | 106.5 | 124.9 | (104.5-148.0) |  | Female | 14 | 13.2 | 105.9 | (57.8-177.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 12.4 | 96.4 | (49.8-168.4) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 4 | 5.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 30.5 | 101.8 | (69.1-144.5) |  |  |  |  |  |  |
| Female | 32 | 30.8 | 104.0 | (71.1-146.9) |  | Female | 9 | 9.7 | 93.0 | (42.4-176.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 7.2 | 69.3 | (22.3-161.6) |  | Male | 13 | 9.3 | 140.3 | (74.6-239.9) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 10 | 9.8 | 102.0 | (48.8-187.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 111 | 94.8 | 117.1 | (96.3-141.0) |
| Female | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 18 | 14.6 | 122.9 | (72.8-194.3) |  | Male | 6 | 6.4 | 93.8 | (34.3-204.3) |
| Female | 4 | 8.5 | nc | (nc-nc) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 4.0 | 150.6 | (55.0-327.9) |  | Male | 6 | 3.4 | 179.1 | (65.4-389.7) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 10.9 | 64.5 | (25.8-132.8) |  | Male | 6 | 6.7 | 89.5 | (32.7-194.8) |
| Female | 10 | 8.0 | 125.2 | (60.0-230.3) |  | Female | 20 | 19.0 | 105.1 | (64.2-162.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 9.2 | 76.1 | (30.5-156.9) |  |  |  |  |  |  |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 26 | 23.9 | 108.9 | (71.1-159.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 43 | 49.0 | 87.7 | (63.5-118.2) |  | Male | 374 | 360.4 | 103.8 | (93.5-114.9) |
| Female | 48 | 51.1 | 93.9 | (69.2-124.4) |  | Female | 382 | 363.1 | 105.2 | (94.9-116.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

316

# Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 56 | 54.5 | 102.7 | (77.5-133.3) |  | Male | 32 | 36.6 | 87.5 | (59.8-123.5) |
| Female | 20 | 21.0 | 95.0 | (58.0-146.8) |  | Female | 15 | 31.5 | 47.7 | (26.7-78.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 11.1 | 99.4 | (49.5-177.9) |  | Male | 11 | 10.4 | 106.2 | (52.9-190.0) |
| Female | 14 | 9.6 | 146.3 | (79.9-245.4) |  | Female | 4 | 8.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 27 | 32.5 | 83.1 | (54.8-121.0) |
| Female | 229 | 221.0 | 103.6 | (90.6-117.9) |  | Female | 36 | 28.2 | 127.5 | (89.3-176.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 23 | 25.2 | 91.3 | (57.8-136.9) |
| Female | 11 | 8.3 | 132.6 | (66.1-237.2) |  | Female | 6 | 11.6 | 51.7 | (18.9-112.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 57 | 60.5 | 94.3 | (71.4-122.1) |  |  |  |  |  |  |
| Female | 62 | 64.3 | 96.4 | (73.9-123.6) |  | Female | 19 | 20.8 | 91.5 | (55.1-142.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 14.5 | 96.7 | (52.8-162.2) |  | Male | 20 | 18.5 | 107.9 | (65.9-166.7) |
| Female | 2 | 4.0 | nc | (nc-nc) |  | Female | 23 | 20.6 | 111.6 | (70.7-167.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 5.9 | nc | (nc-nc) |  | Male | 162 | 192.5 | 84.2 | (71.7-98.2) |
| Female | 6 | 4.9 | 122.1 | (44.6-265.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 35 | 29.9 | 116.9 | (81.4-162.6) |  | Male | 16 | 12.8 | 125.1 | (71.5-203.1) |
| Female | 15 | 17.9 | 83.8 | (46.9-138.2) |  | Female | 9 | 8.1 | 110.5 | (50.4-209.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 8.0 | 99.8 | (43.0-196.6) |  | Male | 11 | 11.2 | 98.0 | (48.8-175.3) |
| Female | 2 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 22.6 | 88.4 | (54.0-136.5) |  | Male | 15 | 15.2 | 98.8 | (55.3-163.0) |
| Female | 16 | 17.3 | 92.6 | (52.9-150.4) |  | Female | 46 | 46.1 | 99.7 | (73.0-133.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 18 | 18.4 | 97.6 | (57.8-154.3) |  |  |  |  |  |  |
| Female | 6 | 6.3 | 95.6 | (34.9-208.0) |  | Female | 39 | 50.2 | 77.7 | (55.2-106.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 102 | 98.2 | 103.9 | (84.7-126.1) |  | Male | 692 | 737.4 | 93.8 | (87.0-101.1) |
| Female | 113 | 107.2 | 105.4 | (86.8-126.7) |  | Female | 753 | 773.2 | 97.4 | (90.6-104.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

317

# Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 11.2 | 53.7 | (19.6-117.0) |  | Male | 4 | 7.3 | nc | (nc-nc) |
| Female | 5 | 4.0 | 126.4 | (40.7-295.0) |  | Female | 3 | 5.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 6 | 6.4 | 93.7 | (34.2-203.9) |
| Female | 30 | 42.9 | 70.0 | (47.2-99.9) |  | Female | 6 | 5.3 | 113.2 | (41.3-246.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.2 | 96.6 | (31.1-225.4) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 12.4 | 112.9 | (61.7-189.5) |  |  |  |  |  |  |
| Female | 15 | 12.1 | 124.2 | (69.5-204.8) |  | Female | 5 | 3.9 | 126.8 | (40.9-295.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 7 | 3.8 | 182.8 | (73.2-376.7) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 6 | 3.9 | 155.3 | (56.7-338.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 30 | 40.5 | 74.2 | (50.0-105.9) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.1 | 98.6 | (36.0-214.6) |  | Male | 4 | 2.6 | nc | (nc-nc) |
| Female | 8 | 3.4 | 233.8 | (100.7-460.7) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 3 | 8.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 7 | 9.9 | 71.0 | (28.4-146.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 20.2 | 99.2 | (60.6-153.2) |  | Male | 134 | 149.5 | 89.6 | (75.1-106.2) |
| Female | 20 | 20.4 | 97.8 | (59.7-151.1) |  | Female | 132 | 146.0 | 90.4 | (75.7-107.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

318

# Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 42 | 28.0 | 150.0 | (108.1-202.8) |  | Male | 16 | 17.7 | 90.3 | (51.6-146.7) |
| Female | 11 | 9.9 | 110.6 | (55.1-197.9) |  | Female | 15 | 13.6 | 110.0 | (61.5-181.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.9 | 102.0 | (32.9-238.1) |  | Male | 7 | 5.3 | 132.4 | (53.0-272.8) |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 22 | 15.5 | 141.9 | (88.9-214.8) |
| Female | 94 | 106.6 | 88.2 | (71.3-107.9) |  | Female | 9 | 13.2 | 68.1 | (31.1-129.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 12.4 | 136.7 | (79.6-218.9) |
| Female | 2 | 3.5 | nc | (nc-nc) |  | Female | 6 | 5.5 | 109.0 | (39.8-237.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 42 | 30.1 | 139.6 | (100.6-188.7) |  |  |  |  |  |  |
| Female | 39 | 29.8 | 131.0 | (93.1-179.1) |  | Female | 11 | 9.8 | 112.7 | (56.2-201.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 7.5 | 146.5 | (73.0-262.1) |  | Male | 16 | 9.5 | 168.4 | (96.2-273.4) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 11 | 9.7 | 113.8 | (56.7-203.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 93 | 101.4 | 91.7 | (74.0-112.3) |
| Female | 3 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 14.8 | 114.9 | (66.9-184.0) |  | Male | 7 | 6.5 | 108.4 | (43.4-223.3) |
| Female | 11 | 8.6 | 128.6 | (64.1-230.1) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 4.2 | 144.5 | (52.8-314.5) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 4 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 10.7 | 102.9 | (51.3-184.1) |  | Male | 5 | 6.4 | 78.1 | (25.2-182.3) |
| Female | 14 | 7.7 | 181.8 | (99.3-305.1) |  | Female | 16 | 18.6 | 85.9 | (49.1-139.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 9.4 | 139.0 | (73.9-237.7) |  |  |  |  |  |  |
| Female | 6 | 3.0 | 198.9 | (72.6-432.9) |  | Female | 21 | 24.8 | 84.5 | (52.3-129.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 82 | 51.4 | 159.6 | (126.9-198.1) |  | Male | 446 | 369.0 | 120.9 | (109.9-132.6) |
| Female | 83 | 52.4 | 158.5 | (126.3-196.5) |  | Female | 397 | 362.4 | 109.5 | (99.0-120.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

319

# Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.3 | 112.2 | (41.0-244.2) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 19 | 20.1 | 94.7 | (57.0-148.0) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 6.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 5.2 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 7 | 1.8 | 379.3 | (152.0-781.5) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 13 | 19.8 | 65.6 | (34.9-112.1) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 6 | 4.5 | 133.0 | (48.6-289.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 9.8 | 122.2 | (63.0-213.4) |  | Male | 59 | 73.3 | 80.5 | (61.3-103.9) |
| Female | 12 | 8.9 | 134.6 | (69.5-235.2) |  | Female | 54 | 66.1 | 81.7 | (61.4-106.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

320

# Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 4.2 | 118.0 | (38.0-275.4) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 13 | 14.8 | 87.9 | (46.7-150.3) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 11 | 12.2 | 90.2 | (45.0-161.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

321

# Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 2 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 5 | 10.9 | 46.0 | (14.8-107.4) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 8 | 8.4 | 95.3 | (41.1-187.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

322

# Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 42 | 33.1 | 126.9 | (91.4-171.5) |  | Male | 15 | 21.5 | 69.8 | (39.0-115.1) |
| Female | 12 | 13.8 | 86.9 | (44.8-151.8) |  | Female | 19 | 19.8 | 96.2 | (57.9-150.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 6.2 | 162.3 | (77.7-298.5) |  | Male | 7 | 6.2 | 113.5 | (45.5-233.9) |
| Female | 10 | 5.9 | 170.0 | (81.4-312.7) |  | Female | 6 | 5.8 | 103.2 | (37.7-224.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 16 | 18.9 | 84.5 | (48.3-137.3) |
| Female | 146 | 141.9 | 102.9 | (86.9-121.0) |  | Female | 20 | 18.2 | 109.7 | (67.0-169.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 14.4 | 117.9 | (68.6-188.7) |
| Female | 8 | 5.3 | 151.9 | (65.4-299.3) |  | Female | 4 | 7.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 41 | 36.0 | 113.7 | (81.6-154.3) |  |  |  |  |  |  |
| Female | 38 | 41.8 | 90.9 | (64.3-124.8) |  | Female | 18 | 13.2 | 136.7 | (81.0-216.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 8.5 | 105.7 | (48.2-200.7) |  | Male | 14 | 11.1 | 126.5 | (69.1-212.2) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 22 | 13.5 | 163.4 | (102.4-247.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 96 | 111.0 | 86.5 | (70.0-105.6) |
| Female | 2 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 17.4 | 126.7 | (79.3-191.8) |  | Male | 8 | 7.6 | 104.6 | (45.0-206.1) |
| Female | 4 | 11.6 | nc | (nc-nc) |  | Female | 9 | 5.3 | 170.7 | (77.9-324.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 4.7 | 127.9 | (46.7-278.4) |  | Male | 6 | 5.5 | 109.3 | (39.9-237.9) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 13.1 | 76.3 | (36.5-140.3) |  | Male | 12 | 8.3 | 143.7 | (74.2-251.1) |
| Female | 11 | 10.9 | 100.7 | (50.2-180.2) |  | Female | 23 | 28.2 | 81.6 | (51.7-122.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 10.7 | 93.8 | (44.9-172.5) |  |  |  |  |  |  |
| Female | 7 | 4.1 | 171.5 | (68.7-353.3) |  | Female | 31 | 32.2 | 96.4 | (65.5-136.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 60 | 58.9 | 101.9 | (77.8-131.2) |  | Male | 431 | 431.0 | 100.0 | (90.8-109.9) |
| Female | 71 | 70.6 | 100.5 | (78.5-126.8) |  | Female | 503 | 496.8 | 101.3 | (92.6-110.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

323

# Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 17.2 | 46.4 | (20.0-91.5) |  | Male | 14 | 10.7 | 130.8 | (71.5-219.5) |
| Female | 6 | 5.7 | 104.8 | (38.3-228.1) |  | Female | 13 | 7.8 | 166.2 | (88.4-284.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 5 | 3.2 | 155.0 | (50.0-361.7) |
| Female | 5 | 2.5 | 203.1 | (65.4-473.9) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 11 | 9.5 | 115.9 | (57.8-207.4) |
| Female | 75 | 62.7 | 119.5 | (94.0-149.8) |  | Female | 12 | 7.6 | 157.4 | (81.3-275.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 7.5 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 18.6 | 69.7 | (37.1-119.2) |  |  |  |  |  |  |
| Female | 10 | 17.4 | 57.4 | (27.5-105.5) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.5 | nc | (nc-nc) |  | Male | 5 | 5.8 | 86.5 | (27.9-201.9) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 5 | 5.6 | 89.5 | (28.8-208.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 63 | 59.6 | 105.7 | (81.2-135.2) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 8.9 | 101.5 | (46.3-192.6) |  | Male | 3 | 4.0 | nc | (nc-nc) |
| Female | 5 | 5.0 | 100.9 | (32.5-235.5) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 6.6 | 122.0 | (52.5-240.4) |  | Male | 7 | 3.8 | 185.6 | (74.4-382.5) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 13 | 10.7 | 121.4 | (64.6-207.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 10 | 14.5 | 69.1 | (33.1-127.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 30.9 | 58.3 | (34.5-92.1) |  | Male | 193 | 222.2 | 86.9 | (75.0-100.0) |
| Female | 18 | 29.6 | 60.7 | (36.0-96.0) |  | Female | 194 | 210.5 | 92.2 | (79.7-106.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

324

# Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 19.2 | 166.8 | (114.0-235.4) |  | Male | 11 | 12.2 | 90.0 | (44.9-161.0) |
| Female | 9 | 7.5 | 119.7 | (54.6-227.3) |  | Female | 5 | 10.0 | 50.0 | (16.1-116.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.5 | nc | (nc-nc) |  | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 0.6 | nc | (nc-nc) |  | Male | 11 | 10.9 | 101.3 | (50.5-181.3) |
| Female | 83 | 74.3 | 111.6 | (88.9-138.4) |  | Female | 7 | 9.7 | 72.4 | (29.0-149.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 8.5 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 5 | 4.0 | 126.5 | (40.8-295.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 21.1 | 128.2 | (84.5-186.6) |  |  |  |  |  |  |
| Female | 27 | 23.1 | 116.8 | (77.0-170.0) |  | Female | 9 | 6.9 | 129.8 | (59.2-246.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 5.0 | 99.8 | (32.2-232.9) |  | Male | 7 | 6.5 | 108.1 | (43.3-222.7) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 6 | 7.5 | 80.4 | (29.4-175.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.5 | nc | (nc-nc) |  | Male | 61 | 66.2 | 92.1 | (70.4-118.3) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 10.1 | 89.3 | (40.8-169.6) |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 9 | 6.1 | 148.4 | (67.7-281.8) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 2.7 | 181.9 | (58.6-424.4) |  | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 7.6 | 172.0 | (91.5-294.1) |  | Male | 7 | 4.6 | 152.2 | (61.0-313.5) |
| Female | 7 | 5.9 | 118.2 | (47.4-243.6) |  | Female | 15 | 13.4 | 111.9 | (62.6-184.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 6.3 | 127.4 | (54.8-251.0) |  |  |  |  |  |  |
| Female | 7 | 2.2 | 324.5 | (130.0-668.6) |  | Female | 20 | 16.7 | 119.5 | (72.9-184.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 42 | 34.1 | 123.3 | (88.9-166.7) |  | Male | 281 | 250.6 | 112.1 | (99.4-126.1) |
| Female | 43 | 36.6 | 117.3 | (84.9-158.1) |  | Female | 288 | 261.3 | 110.2 | (97.9-123.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

325

# Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 28.4 | 74.0 | (45.8-113.1) |  | Male | 28 | 18.0 | 155.3 | (103.2-224.5) |
| Female | 9 | 10.8 | 83.6 | (38.1-158.6) |  | Female | 27 | 15.1 | 179.3 | (118.2-260.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  | Male | 3 | 5.4 | nc | (nc-nc) |
| Female | 3 | 4.9 | nc | (nc-nc) |  | Female | 8 | 4.6 | 175.7 | (75.6-346.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 23 | 16.0 | 143.5 | (91.0-215.4) |
| Female | 129 | 114.7 | 112.5 | (93.9-133.7) |  | Female | 13 | 14.3 | 90.7 | (48.2-155.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 12.8 | 39.0 | (12.6-91.0) |
| Female | 2 | 3.8 | nc | (nc-nc) |  | Female | 5 | 5.9 | 84.2 | (27.1-196.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 31.0 | 54.8 | (31.9-87.7) |  |  |  |  |  |  |
| Female | 22 | 32.9 | 66.8 | (41.9-101.2) |  | Female | 7 | 10.6 | 66.1 | (26.5-136.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 7.6 | nc | (nc-nc) |  | Male | 8 | 9.6 | 83.0 | (35.8-163.7) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 7 | 10.5 | 66.4 | (26.6-136.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 118 | 101.3 | 116.5 | (96.4-139.5) |
| Female | 5 | 2.3 | 221.1 | (71.3-516.1) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 15.1 | 52.8 | (22.7-104.1) |  | Male | 5 | 6.6 | 75.8 | (24.4-176.9) |
| Female | 9 | 9.2 | 97.9 | (44.7-185.8) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 11.3 | 97.6 | (48.7-174.7) |  | Male | 12 | 6.6 | 180.5 | (93.2-315.3) |
| Female | 13 | 8.9 | 146.8 | (78.1-251.1) |  | Female | 22 | 21.2 | 104.0 | (65.1-157.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 9.5 | 63.1 | (23.0-137.4) |  |  |  |  |  |  |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 16 | 25.9 | 61.8 | (35.3-100.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 51.4 | 38.9 | (23.8-60.1) |  | Male | 328 | 374.8 | 87.5 | (78.3-97.5) |
| Female | 33 | 55.2 | 59.8 | (41.1-83.9) |  | Female | 368 | 393.5 | 93.5 | (84.2-103.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

326

# Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 5.1 | 156.2 | (67.2-307.7) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 5 | 2.2 | 222.6 | (71.7-519.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 19 | 18.2 | 104.5 | (62.9-163.2) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 5.3 | 208.0 | (103.7-372.3) |  |  |  |  |  |  |
| Female | 6 | 5.4 | 110.9 | (40.5-241.4) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 21 | 18.2 | 115.6 | (71.5-176.7) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 9.3 | nc | (nc-nc) |  | Male | 64 | 64.9 | 98.7 | (76.0-126.0) |
| Female | 12 | 10.0 | 120.4 | (62.1-210.3) |  | Female | 66 | 63.6 | 103.8 | (80.3-132.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

327

# Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 4.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 4.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 11 | 14.8 | 74.5 | (37.1-133.3) |
| Female | 4 | 1.6 | nc | (nc-nc) |  | Female | 9 | 12.6 | 71.4 | (32.6-135.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

328

# Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 5.0 | 159.5 | (68.7-314.4) |  | Male | 7 | 3.1 | 226.8 | (90.9-467.4) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 6 | 2.4 | 245.7 | (89.7-534.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 17 | 18.2 | 93.4 | (54.4-149.6) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 5.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 5.4 | 110.9 | (40.5-241.4) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 18 | 16.5 | 109.3 | (64.8-172.8) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 4 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 8.8 | 56.5 | (18.2-131.9) |  | Male | 63 | 63.7 | 98.9 | (76.0-126.6) |
| Female | 12 | 9.0 | 133.3 | (68.8-232.9) |  | Female | 72 | 63.5 | 113.4 | (88.8-142.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

329

# West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 11.1 | 143.5 | (82.0-233.1) |  | Male | 3 | 7.1 | nc | (nc-nc) |
| Female | 5 | 3.6 | 139.5 | (45.0-325.5) |  | Female | 0 | 4.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 6.3 | 79.4 | (25.6-185.2) |
| Female | 37 | 34.1 | 108.4 | (76.3-149.4) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 5.0 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 12.4 | 40.4 | (13.0-94.3) |  |  |  |  |  |  |
| Female | 4 | 10.8 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 26 | 37.7 | 69.0 | (45.0-101.1) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.8 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 9 | 5.5 | 162.5 | (74.2-308.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 7 | 7.8 | 90.2 | (36.1-185.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 19.6 | 96.7 | (58.2-151.1) |  | Male | 111 | 144.4 | 76.9 | (63.2-92.6) |
| Female | 15 | 17.7 | 84.9 | (47.5-140.1) |  | Female | 111 | 120.7 | 92.0 | (75.7-110.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

330

# West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 9.4 | 85.5 | (36.8-168.5) |  | Male | 9 | 5.8 | 155.2 | (70.8-294.7) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 5 | 4.3 | 117.0 | (37.7-273.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.1 | 117.4 | (42.9-255.6) |
| Female | 23 | 32.9 | 69.9 | (44.3-104.8) |  | Female | 7 | 4.3 | 164.6 | (65.9-339.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 10.0 | 80.2 | (34.5-158.0) |  |  |  |  |  |  |
| Female | 16 | 10.1 | 159.2 | (90.9-258.5) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 2.4 | 208.6 | (67.2-486.7) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 32 | 31.4 | 102.0 | (69.8-144.0) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 3.5 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 9 | 5.6 | 159.6 | (72.8-303.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 7 | 7.4 | 94.4 | (37.8-194.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 16.7 | 95.7 | (54.7-155.4) |  | Male | 115 | 119.0 | 96.7 | (79.8-116.0) |
| Female | 21 | 16.4 | 127.7 | (79.0-195.2) |  | Female | 118 | 114.8 | 102.8 | (85.1-123.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

331

# West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 0 | 3.2 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 3 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 15 | 19.6 | 76.6 | (42.8-126.3) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 5.5 | 108.2 | (39.5-235.4) |  |  |  |  |  |  |
| Female | 3 | 6.2 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 13 | 18.2 | 71.4 | (38.0-122.1) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 5 | 4.5 | 111.2 | (35.8-259.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 9.3 | 107.2 | (51.3-197.2) |  | Male | 45 | 66.9 | 67.3 | (49.1-90.0) |
| Female | 15 | 10.1 | 148.1 | (82.8-244.3) |  | Female | 59 | 69.2 | 85.3 | (64.9-110.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

332

# West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 5 | 2.3 | 216.6 | (69.8-505.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 0.9 | nc | (nc-nc) |  | Male | 3 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 21 | 18.9 | 111.0 | (68.7-169.7) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 4.5 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 17 | 18.8 | 90.4 | (52.6-144.8) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 6 | 4.4 | 135.3 | (49.4-294.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 8.4 | nc | (nc-nc) |  | Male | 49 | 65.1 | 75.3 | (55.7-99.5) |
| Female | 7 | 7.8 | 89.4 | (35.8-184.2) |  | Female | 53 | 59.8 | 88.6 | (66.4-115.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

333

# West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 32.1 | 112.2 | (78.6-155.4) |  | Male | 14 | 20.7 | 67.8 | (37.0-113.7) |
| Female | 10 | 12.0 | 83.6 | (40.0-153.8) |  | Female | 14 | 16.5 | 85.1 | (46.5-142.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.9 | 84.2 | (27.1-196.5) |  | Male | 4 | 6.1 | nc | (nc-nc) |
| Female | 4 | 5.1 | nc | (nc-nc) |  | Female | 3 | 5.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 12 | 18.2 | 65.8 | (34.0-115.0) |
| Female | 113 | 123.4 | 91.6 | (75.5-110.1) |  | Female | 11 | 15.7 | 70.1 | (35.0-125.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 14.5 | 152.2 | (95.3-230.4) |
| Female | 12 | 4.2 | 282.9 | (146.0-494.3) |  | Female | 9 | 6.5 | 139.1 | (63.5-264.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 32 | 35.1 | 91.2 | (62.3-128.7) |  |  |  |  |  |  |
| Female | 35 | 36.3 | 96.4 | (67.1-134.0) |  | Female | 7 | 11.4 | 61.3 | (24.6-126.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 8.5 | 152.8 | (81.3-261.3) |  | Male | 10 | 10.9 | 92.1 | (44.1-169.5) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 8 | 11.7 | 68.4 | (29.4-134.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 92 | 113.0 | 81.4 | (65.7-99.9) |
| Female | 1 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 17.1 | 70.2 | (36.3-122.7) |  | Male | 6 | 7.4 | 80.5 | (29.4-175.3) |
| Female | 8 | 10.0 | 80.0 | (34.4-157.6) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  | Male | 5 | 4.2 | 117.8 | (38.0-274.8) |
| Female | 2 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 12.7 | 71.1 | (32.4-134.9) |  | Male | 8 | 7.8 | 102.1 | (44.0-201.3) |
| Female | 6 | 9.5 | 63.4 | (23.1-137.9) |  | Female | 19 | 22.7 | 83.8 | (50.4-130.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 10.8 | 111.3 | (57.5-194.5) |  |  |  |  |  |  |
| Female | 0 | 3.5 | nc | (nc-nc) |  | Female | 28 | 28.1 | 99.6 | (66.2-144.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 54 | 58.0 | 93.2 | (70.0-121.6) |  | Male | 379 | 423.7 | 89.5 | (80.7-98.9) |
| Female | 76 | 60.8 | 125.0 | (98.5-156.4) |  | Female | 403 | 427.9 | 94.2 | (85.2-103.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

334

# West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 3 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 8 | 7.7 | 103.4 | (44.5-203.8) |  | Female | 4 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 11 | 8.2 | 134.1 | (66.9-240.0) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  | Male | 30 | 29.4 | 101.9 | (68.8-145.5) |
| Female | 3 | 3.7 | nc | (nc-nc) |  | Female | 26 | 25.7 | 101.3 | (66.2-148.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

335

# West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 17 | 13.4 | 126.6 | (73.7-202.8) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.2 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 13 | 14.4 | 90.1 | (47.9-154.1) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 3 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 6.6 | nc | (nc-nc) |  | Male | 46 | 49.5 | 93.0 | (68.1-124.0) |
| Female | 6 | 5.9 | 102.3 | (37.4-222.7) |  | Female | 50 | 43.3 | 115.6 | (85.8-152.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

336

# Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 17.7 | 96.0 | (55.9-153.7) |  | Male | 9 | 11.9 | 75.8 | (34.6-144.0) |
| Female | 7 | 6.9 | 101.6 | (40.7-209.4) |  | Female | 5 | 9.9 | 50.6 | (16.3-118.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 6 | 3.4 | 175.0 | (63.9-380.9) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 12 | 10.6 | 113.6 | (58.6-198.4) |
| Female | 75 | 74.0 | 101.3 | (79.7-127.0) |  | Female | 7 | 9.2 | 76.4 | (30.6-157.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 8.5 | 70.2 | (25.6-152.8) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 1 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 20.3 | 83.9 | (48.8-134.3) |  |  |  |  |  |  |
| Female | 31 | 21.7 | 143.0 | (97.1-202.9) |  | Female | 6 | 6.8 | 88.8 | (32.4-193.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.8 | 104.8 | (33.8-244.5) |  | Male | 4 | 6.1 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 5 | 6.8 | 73.3 | (23.6-171.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 45 | 63.1 | 71.3 | (52.0-95.4) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 10.0 | 80.1 | (34.5-157.9) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 2 | 5.8 | nc | (nc-nc) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 1 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 7.3 | 122.7 | (56.0-232.9) |  | Male | 9 | 4.8 | 186.9 | (85.3-354.8) |
| Female | 6 | 5.7 | 106.0 | (38.7-230.7) |  | Female | 9 | 14.3 | 63.0 | (28.8-119.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.2 | 80.6 | (26.0-188.1) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 19 | 16.2 | 117.5 | (70.7-183.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 31.7 | 59.9 | (36.1-93.6) |  | Male | 203 | 240.3 | 84.5 | (73.3-96.9) |
| Female | 34 | 34.0 | 100.1 | (69.3-139.9) |  | Female | 236 | 252.5 | 93.5 | (81.9-106.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

337

# Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 40 | 42.1 | 95.0 | (67.8-129.3) |  | Male | 24 | 27.4 | 87.5 | (56.0-130.2) |
| Female | 9 | 15.7 | 57.2 | (26.1-108.5) |  | Female | 18 | 22.3 | 80.9 | (47.9-127.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 8.1 | nc | (nc-nc) |  | Male | 9 | 8.0 | 112.3 | (51.3-213.2) |
| Female | 7 | 7.0 | 100.1 | (40.1-206.3) |  | Female | 3 | 6.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 17 | 24.4 | 69.7 | (40.6-111.6) |
| Female | 183 | 167.2 | 109.5 | (94.2-126.5) |  | Female | 17 | 21.0 | 81.1 | (47.2-129.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 19.6 | 66.4 | (35.3-113.6) |
| Female | 8 | 5.8 | 138.9 | (59.8-273.6) |  | Female | 8 | 8.7 | 91.9 | (39.6-181.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 46 | 46.7 | 98.4 | (72.1-131.3) |  |  |  |  |  |  |
| Female | 55 | 48.0 | 114.6 | (86.3-149.2) |  | Female | 17 | 15.5 | 109.8 | (63.9-175.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 14 | 11.3 | 123.4 | (67.4-207.1) |  | Male | 7 | 14.4 | 48.6 | (19.5-100.2) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 12 | 15.4 | 77.9 | (40.2-136.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 3.6 | 219.9 | (94.7-433.3) |  | Male | 128 | 152.7 | 83.8 | (69.9-99.7) |
| Female | 3 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 22.9 | 61.0 | (33.3-102.4) |  | Male | 14 | 9.9 | 141.8 | (77.5-237.9) |
| Female | 13 | 13.4 | 97.0 | (51.6-165.8) |  | Female | 4 | 6.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 6.3 | nc | (nc-nc) |  | Male | 4 | 6.0 | nc | (nc-nc) |
| Female | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 17.0 | 94.1 | (53.7-152.8) |  | Male | 5 | 10.7 | 46.7 | (15.1-109.0) |
| Female | 13 | 12.7 | 102.4 | (54.5-175.2) |  | Female | 19 | 31.3 | 60.7 | (36.5-94.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 14.4 | 76.4 | (38.1-136.7) |  |  |  |  |  |  |
| Female | 4 | 4.7 | nc | (nc-nc) |  | Female | 34 | 38.3 | 88.8 | (61.5-124.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 79 | 76.1 | 103.8 | (82.2-129.4) |  | Male | 499 | 566.4 | 88.1 | (80.5-96.2) |
| Female | 78 | 80.5 | 96.8 | (76.6-120.9) |  | Female | 546 | 574.7 | 95.0 | (87.2-103.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

338

# Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 18.9 | 58.2 | (29.0-104.2) |  | Male | 19 | 13.7 | 139.1 | (83.7-217.2) |
| Female | 2 | 6.3 | nc | (nc-nc) |  | Female | 10 | 10.8 | 92.8 | (44.4-170.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.3 | 115.3 | (37.2-269.2) |  | Male | 7 | 3.9 | 177.3 | (71.0-365.3) |
| Female | 5 | 3.4 | 148.2 | (47.8-345.8) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 0.6 | nc | (nc-nc) |  | Male | 12 | 12.1 | 99.6 | (51.4-174.0) |
| Female | 89 | 86.9 | 102.4 | (82.2-126.0) |  | Female | 7 | 9.3 | 75.3 | (30.2-155.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 14 | 10.7 | 130.2 | (71.1-218.5) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 23.1 | 99.7 | (63.2-149.6) |  |  |  |  |  |  |
| Female | 18 | 20.0 | 89.8 | (53.2-142.0) |  | Female | 5 | 7.6 | 66.0 | (21.3-154.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.7 | nc | (nc-nc) |  | Male | 7 | 6.8 | 102.3 | (41.0-210.7) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 7 | 6.0 | 116.4 | (46.6-239.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 80 | 79.2 | 101.1 | (80.1-125.8) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 12.3 | 81.4 | (39.0-149.7) |  | Male | 7 | 4.7 | 147.6 | (59.1-304.1) |
| Female | 2 | 6.4 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 8.2 | 134.6 | (67.1-240.9) |  | Male | 7 | 6.0 | 116.3 | (46.6-239.6) |
| Female | 11 | 5.5 | 199.2 | (99.3-356.4) |  | Female | 19 | 17.5 | 108.5 | (65.3-169.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 7.6 | 78.7 | (28.7-171.2) |  |  |  |  |  |  |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 32 | 19.4 | 164.7 | (112.6-232.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 36.0 | 89.0 | (60.9-125.7) |  | Male | 286 | 281.7 | 101.5 | (90.1-114.0) |
| Female | 29 | 34.9 | 83.0 | (55.6-119.2) |  | Female | 267 | 271.7 | 98.3 | (86.8-110.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

339

# Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 10 | 7.6 | 130.8 | (62.6-240.6) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 10 | 7.5 | 132.9 | (63.6-244.4) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 25 | 26.3 | 94.9 | (61.4-140.1) |
| Female | 0 | 3.3 | nc | (nc-nc) |  | Female | 14 | 24.5 | 57.2 | (31.2-95.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

340

# Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 7.6 | 105.9 | (45.6-208.6) |  | Male | 8 | 5.2 | 153.8 | (66.2-303.0) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 8 | 3.9 | 206.1 | (88.7-406.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 7 | 4.6 | 153.0 | (61.3-315.2) |
| Female | 40 | 30.5 | 131.0 | (93.6-178.4) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 8.8 | 125.6 | (62.6-224.7) |  |  |  |  |  |  |
| Female | 6 | 7.6 | 78.5 | (28.7-170.8) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 3 | 0.5 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 26 | 30.7 | 84.7 | (55.3-124.1) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.6 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 4 | 6.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 6 | 7.1 | 84.7 | (30.9-184.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 14.1 | 77.9 | (38.9-139.5) |  | Male | 108 | 108.3 | 99.7 | (81.8-120.4) |
| Female | 14 | 12.9 | 108.5 | (59.3-182.1) |  | Female | 103 | 98.6 | 104.5 | (85.3-126.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

341

# Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 16.5 | 90.8 | (50.8-149.8) |  | Male | 12 | 9.8 | 122.3 | (63.1-213.6) |
| Female | 3 | 5.1 | nc | (nc-nc) |  | Female | 11 | 6.6 | 165.4 | (82.5-296.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 2.6 | 227.4 | (83.0-495.0) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 8 | 8.7 | 91.7 | (39.5-180.7) |
| Female | 60 | 52.9 | 113.5 | (86.6-146.1) |  | Female | 4 | 6.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.6 | 90.4 | (33.0-196.9) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 17.4 | 51.8 | (23.6-98.3) |  |  |  |  |  |  |
| Female | 15 | 15.6 | 96.2 | (53.8-158.7) |  | Female | 3 | 4.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 4.1 | nc | (nc-nc) |  | Male | 5 | 5.4 | 92.0 | (29.7-214.8) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 10 | 5.0 | 199.3 | (95.4-366.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 59 | 53.6 | 110.2 | (83.9-142.1) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 7.9 | nc | (nc-nc) |  | Male | 1 | 3.7 | nc | (nc-nc) |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 6.1 | 146.7 | (67.0-278.5) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 9 | 4.0 | 225.9 | (103.1-428.9) |  | Female | 8 | 8.7 | 91.9 | (39.6-181.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 5 | 12.0 | 41.7 | (13.4-97.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 29.2 | 78.9 | (50.0-118.4) |  | Male | 188 | 204.1 | 92.1 | (79.4-106.3) |
| Female | 24 | 25.9 | 92.6 | (59.3-137.8) |  | Female | 179 | 181.0 | 98.9 | (85.0-114.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

342

# Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 30 | 22.3 | 134.2 | (90.6-191.7) |  | Male | 16 | 13.9 | 114.8 | (65.6-186.4) |
| Female | 11 | 7.4 | 149.5 | (74.5-267.4) |  | Female | 14 | 9.9 | 141.3 | (77.2-237.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 6 | 4.2 | 143.2 | (52.3-311.7) |
| Female | 0 | 3.1 | nc | (nc-nc) |  | Female | 5 | 3.1 | 159.0 | (51.3-371.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 12 | 12.2 | 98.2 | (50.7-171.5) |
| Female | 68 | 78.4 | 86.8 | (67.4-110.0) |  | Female | 15 | 9.7 | 153.9 | (86.1-253.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 9.7 | 71.9 | (28.8-148.2) |
| Female | 6 | 2.6 | 234.5 | (85.6-510.4) |  | Female | 6 | 4.1 | 148.1 | (54.1-322.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 23.8 | 96.6 | (61.2-145.0) |  |  |  |  |  |  |
| Female | 14 | 21.8 | 64.1 | (35.0-107.6) |  | Female | 3 | 7.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 6.0 | 151.0 | (68.9-286.7) |  | Male | 9 | 7.6 | 119.2 | (54.4-226.2) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 6 | 7.2 | 83.8 | (30.6-182.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 91 | 80.7 | 112.8 | (90.8-138.5) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 11.6 | 111.7 | (59.4-191.1) |  | Male | 5 | 5.1 | 97.5 | (31.4-227.5) |
| Female | 6 | 6.3 | 95.2 | (34.8-207.3) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 3.3 | 152.6 | (49.2-356.1) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 8.3 | 96.0 | (41.3-189.1) |  | Male | 8 | 4.9 | 162.1 | (69.8-319.4) |
| Female | 4 | 5.6 | nc | (nc-nc) |  | Female | 14 | 13.3 | 105.0 | (57.3-176.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 7.3 | 68.5 | (22.1-159.9) |  |  |  |  |  |  |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 17 | 18.4 | 92.5 | (53.9-148.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 30 | 40.7 | 73.7 | (49.7-105.2) |  | Male | 298 | 291.6 | 102.2 | (90.9-114.5) |
| Female | 32 | 39.0 | 82.1 | (56.2-115.9) |  | Female | 242 | 266.5 | 90.8 | (79.7-103.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

343

# Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 19.6 | 91.7 | (54.3-145.0) |  | Male | 22 | 11.8 | 186.3 | (116.7-282.0) |
| Female | 2 | 7.3 | nc | (nc-nc) |  | Female | 22 | 9.0 | 243.3 | (152.4-368.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 5 | 3.0 | 165.6 | (53.4-386.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 8 | 10.5 | 76.1 | (32.7-149.9) |
| Female | 95 | 70.6 | 134.6 | (108.9-164.6) |  | Female | 6 | 9.2 | 65.0 | (23.7-141.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 7.9 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 7 | 3.7 | 187.1 | (75.0-385.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 20.9 | 119.4 | (77.2-176.2) |  |  |  |  |  |  |
| Female | 26 | 22.4 | 116.1 | (75.8-170.1) |  | Female | 9 | 6.5 | 138.8 | (63.3-263.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 9 | 6.5 | 139.4 | (63.6-264.6) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 3 | 7.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 66 | 61.5 | 107.4 | (83.1-136.6) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 9.4 | 106.1 | (50.8-195.1) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 4 | 5.8 | nc | (nc-nc) |  | Female | 1 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 7.5 | 80.5 | (29.4-175.1) |  | Male | 7 | 4.0 | 177.0 | (70.9-364.7) |
| Female | 7 | 5.6 | 124.1 | (49.7-255.8) |  | Female | 20 | 11.5 | 173.9 | (106.2-268.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 6.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 18 | 15.5 | 115.9 | (68.6-183.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 24 | 34.1 | 70.4 | (45.1-104.7) |  | Male | 249 | 241.5 | 103.1 | (90.7-116.7) |
| Female | 38 | 35.8 | 106.2 | (75.2-145.8) |  | Female | 290 | 247.9 | 117.0 | (103.9-131.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

344

# Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 56 | 58.8 | 95.2 | (71.9-123.6) |  | Male | 42 | 38.2 | 109.9 | (79.2-148.6) |
| Female | 42 | 23.1 | 181.5 | (130.8-245.4) |  | Female | 41 | 32.6 | 125.7 | (90.2-170.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 10.9 | 91.3 | (43.7-168.0) |  | Male | 16 | 11.2 | 143.2 | (81.8-232.6) |
| Female | 13 | 10.0 | 129.8 | (69.1-222.0) |  | Female | 8 | 9.9 | 81.2 | (35.0-160.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 45 | 33.7 | 133.6 | (97.5-178.8) |
| Female | 266 | 248.5 | 107.0 | (94.6-120.7) |  | Female | 26 | 30.9 | 84.2 | (55.0-123.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 34 | 26.8 | 126.7 | (87.7-177.1) |
| Female | 8 | 8.7 | 92.3 | (39.7-181.8) |  | Female | 20 | 12.8 | 155.8 | (95.1-240.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 76 | 65.0 | 117.0 | (92.1-146.4) |  |  |  |  |  |  |
| Female | 82 | 70.5 | 116.4 | (92.6-144.5) |  | Female | 29 | 22.8 | 127.4 | (85.3-183.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 17 | 15.7 | 108.6 | (63.2-173.9) |  | Male | 21 | 20.0 | 105.2 | (65.1-160.8) |
| Female | 1 | 4.4 | nc | (nc-nc) |  | Female | 21 | 22.6 | 93.0 | (57.6-142.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 4.6 | 130.2 | (47.6-283.5) |  | Male | 191 | 208.0 | 91.8 | (79.3-105.8) |
| Female | 1 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 34 | 31.8 | 107.0 | (74.1-149.6) |  | Male | 13 | 13.7 | 94.6 | (50.3-161.7) |
| Female | 29 | 19.9 | 145.9 | (97.7-209.6) |  | Female | 5 | 8.8 | 56.6 | (18.2-132.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 15 | 8.7 | 173.2 | (96.9-285.7) |  | Male | 3 | 7.8 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 21 | 23.3 | 90.3 | (55.9-138.0) |  | Male | 21 | 14.6 | 143.6 | (88.8-219.5) |
| Female | 13 | 18.4 | 70.8 | (37.6-121.0) |  | Female | 54 | 46.0 | 117.4 | (88.2-153.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 19 | 19.8 | 95.8 | (57.6-149.6) |  |  |  |  |  |  |
| Female | 7 | 7.0 | 100.3 | (40.2-206.7) |  | Female | 59 | 56.7 | 104.0 | (79.1-134.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 122 | 106.3 | 114.7 | (95.3-137.0) |  | Male | 832 | 780.7 | 106.6 | (99.5-114.1) |
| Female | 153 | 119.8 | 127.7 | (108.3-149.6) |  | Female | 954 | 848.2 | 112.5 | (105.4-119.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

345

# Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 2 | 7.5 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 7.7 | 64.8 | (20.9-151.3) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 1.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 19 | 27.6 | 68.8 | (41.4-107.5) |
| Female | 1 | 3.4 | nc | (nc-nc) |  | Female | 14 | 24.7 | 56.7 | (31.0-95.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

346

# Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 12.4 | 185.8 | (117.7-278.7) |  | Male | 8 | 8.6 | 92.5 | (39.8-182.3) |
| Female | 5 | 4.5 | 111.4 | (35.9-259.9) |  | Female | 11 | 7.4 | 149.6 | (74.6-267.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 4 | 7.7 | nc | (nc-nc) |
| Female | 49 | 56.1 | 87.3 | (64.6-115.5) |  | Female | 5 | 6.4 | 77.9 | (25.1-181.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.4 | 93.5 | (34.1-203.4) |
| Female | 6 | 2.1 | 283.3 | (103.4-616.6) |  | Female | 7 | 2.7 | 255.8 | (102.5-527.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 14.4 | 110.9 | (63.4-180.2) |  |  |  |  |  |  |
| Female | 20 | 14.0 | 143.3 | (87.5-221.4) |  | Female | 1 | 5.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 3.5 | 198.0 | (79.3-408.0) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 51 | 48.2 | 105.8 | (78.8-139.1) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 7.5 | 200.0 | (111.8-329.9) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 5.3 | 151.0 | (65.0-297.5) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 12 | 11.5 | 103.9 | (53.6-181.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 4.6 | 131.0 | (47.8-285.1) |  |  |  |  |  |  |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 16 | 12.8 | 125.4 | (71.6-203.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 22.9 | 135.4 | (92.0-192.2) |  | Male | 203 | 176.6 | 114.9 | (99.7-131.9) |
| Female | 36 | 24.4 | 147.3 | (103.2-203.9) |  | Female | 190 | 183.1 | 103.8 | (89.6-119.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

347

# Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 20.0 | 74.9 | (41.9-123.6) |  | Male | 22 | 12.2 | 180.5 | (113.1-273.2) |
| Female | 8 | 7.3 | 109.3 | (47.1-215.3) |  | Female | 9 | 9.3 | 97.0 | (44.2-184.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.3 | 153.2 | (49.4-357.6) |  | Male | 5 | 3.7 | 136.1 | (43.9-317.6) |
| Female | 6 | 2.9 | 208.1 | (76.0-452.9) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 12 | 10.8 | 111.1 | (57.3-194.0) |
| Female | 69 | 73.1 | 94.4 | (73.4-119.5) |  | Female | 10 | 9.4 | 106.7 | (51.1-196.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 8.4 | 59.6 | (19.2-139.0) |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 0 | 3.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 21.4 | 74.8 | (42.7-121.5) |  |  |  |  |  |  |
| Female | 21 | 22.2 | 94.6 | (58.5-144.6) |  | Female | 5 | 6.7 | 74.4 | (24.0-173.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  | Male | 7 | 6.7 | 105.2 | (42.1-216.8) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 15 | 7.2 | 208.6 | (116.7-344.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 63 | 66.8 | 94.4 | (72.5-120.7) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 9.9 | 70.8 | (28.4-145.8) |  | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 6 | 5.9 | 100.9 | (36.8-219.7) |  | Female | 0 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 7.5 | nc | (nc-nc) |  | Male | 4 | 4.1 | nc | (nc-nc) |
| Female | 6 | 5.6 | 108.0 | (39.4-235.0) |  | Female | 11 | 11.9 | 92.2 | (46.0-165.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 6.4 | 94.3 | (34.4-205.2) |  |  |  |  |  |  |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 12 | 16.6 | 72.3 | (37.3-126.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 35.5 | 62.1 | (38.9-94.0) |  | Male | 220 | 252.3 | 87.2 | (76.0-99.5) |
| Female | 23 | 36.8 | 62.5 | (39.6-93.8) |  | Female | 225 | 253.5 | 88.8 | (77.5-101.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

348

# Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 16 | 13.3 | 120.6 | (68.9-195.8) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 3.5 | 172.6 | (63.0-375.7) |  | Female | 5 | 1.2 | 415.2 | (133.8-968.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 7 | 12.1 | 58.1 | (23.3-119.7) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 3 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 5.7 | nc | (nc-nc) |  | Male | 27 | 42.5 | 63.5 | (41.8-92.3) |
| Female | 5 | 6.0 | 83.3 | (26.8-194.3) |  | Female | 53 | 43.6 | 121.5 | (91.0-158.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

349

# Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 10.9 | 73.2 | (31.5-144.3) |  | Male | 4 | 6.2 | nc | (nc-nc) |
| Female | 5 | 4.3 | 115.9 | (37.4-270.6) |  | Female | 1 | 5.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 5.6 | 125.4 | (50.2-258.3) |
| Female | 27 | 36.6 | 73.8 | (48.6-107.4) |  | Female | 6 | 5.2 | 114.3 | (41.7-248.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 4.0 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 11.0 | 54.4 | (19.9-118.4) |  |  |  |  |  |  |
| Female | 10 | 12.8 | 78.1 | (37.4-143.6) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 0 | 3.5 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 52 | 33.3 | 156.1 | (116.6-204.7) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 4.7 | 105.4 | (34.0-246.0) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.0 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 4 | 8.4 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 18.7 | 58.9 | (29.4-105.4) |  | Male | 118 | 129.7 | 91.0 | (75.3-109.0) |
| Female | 18 | 20.6 | 87.4 | (51.8-138.2) |  | Female | 101 | 136.4 | 74.0 | (60.3-90.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

350

# Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 22.7 | 127.9 | (85.7-183.7) |  | Male | 9 | 15.1 | 59.4 | (27.1-112.9) |
| Female | 12 | 8.1 | 148.7 | (76.7-259.7) |  | Female | 16 | 12.0 | 133.1 | (76.0-216.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.5 | nc | (nc-nc) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 3 | 3.7 | nc | (nc-nc) |  | Female | 8 | 3.5 | 231.1 | (99.5-455.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 8 | 13.4 | 59.7 | (25.7-117.6) |
| Female | 109 | 93.0 | 117.2 | (96.2-141.4) |  | Female | 16 | 11.0 | 145.2 | (83.0-235.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 10.9 | 100.6 | (50.1-179.9) |
| Female | 1 | 3.3 | nc | (nc-nc) |  | Female | 7 | 4.6 | 151.3 | (60.6-311.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 25.8 | 89.2 | (56.5-133.8) |  |  |  |  |  |  |
| Female | 23 | 25.1 | 91.7 | (58.1-137.6) |  | Female | 7 | 8.3 | 84.0 | (33.6-173.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 6.2 | nc | (nc-nc) |  | Male | 6 | 7.8 | 77.0 | (28.1-167.6) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 10 | 7.8 | 127.6 | (61.1-234.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 70 | 82.4 | 84.9 | (66.2-107.3) |
| Female | 2 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 12.8 | 132.4 | (77.1-212.0) |  | Male | 6 | 5.4 | 111.1 | (40.6-241.9) |
| Female | 9 | 7.2 | 124.5 | (56.8-236.3) |  | Female | 5 | 3.1 | 159.2 | (51.3-371.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 9.2 | 194.8 | (115.4-307.9) |  | Male | 8 | 6.1 | 132.1 | (56.9-260.4) |
| Female | 3 | 6.7 | nc | (nc-nc) |  | Female | 13 | 17.9 | 72.6 | (38.6-124.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 8.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 24 | 20.6 | 116.4 | (74.6-173.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 46 | 41.3 | 111.5 | (81.6-148.7) |  | Male | 299 | 308.7 | 96.9 | (86.2-108.5) |
| Female | 51 | 42.1 | 121.1 | (90.1-159.2) |  | Female | 349 | 309.0 | 112.9 | (101.4-125.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

351

# Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 9.7 | 144.7 | (79.0-242.7) |  | Male | 1 | 6.6 | nc | (nc-nc) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 2 | 5.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 5 | 1.9 | 260.9 | (84.1-608.9) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 4 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 5.9 | nc | (nc-nc) |
| Female | 31 | 39.3 | 78.8 | (53.6-111.9) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 4.9 | 123.5 | (45.1-268.8) |
| Female | 4 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 11.2 | 71.7 | (30.9-141.3) |  |  |  |  |  |  |
| Female | 16 | 10.1 | 157.9 | (90.2-256.4) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 5 | 3.4 | 148.3 | (47.8-346.1) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 7 | 3.1 | 222.2 | (89.0-457.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 33 | 36.5 | 90.5 | (62.3-127.1) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 5.7 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 5 | 3.0 | 164.3 | (52.9-383.4) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.0 | nc | (nc-nc) |  | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 7 | 7.9 | 88.8 | (35.6-182.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 9 | 8.8 | 102.4 | (46.7-194.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 17.8 | 84.1 | (47.0-138.7) |  | Male | 124 | 135.2 | 91.7 | (76.3-109.3) |
| Female | 24 | 17.7 | 135.6 | (86.9-201.8) |  | Female | 136 | 129.6 | 104.9 | (88.0-124.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

352

# Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 25.1 | 91.7 | (58.1-137.6) |  | Male | 19 | 15.8 | 120.3 | (72.4-187.8) |
| Female | 5 | 9.7 | 51.4 | (16.6-119.9) |  | Female | 16 | 12.7 | 125.8 | (71.9-204.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 4.5 | nc | (nc-nc) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 10 | 4.0 | 248.6 | (119.0-457.2) |  | Female | 6 | 4.1 | 148.0 | (54.0-322.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 16 | 14.0 | 114.3 | (65.3-185.6) |
| Female | 99 | 98.9 | 100.1 | (81.4-121.9) |  | Female | 11 | 12.6 | 87.6 | (43.7-156.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 11.0 | 45.5 | (14.7-106.2) |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 5 | 5.1 | 97.2 | (31.3-226.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 27.4 | 113.3 | (76.9-160.8) |  |  |  |  |  |  |
| Female | 23 | 29.9 | 76.9 | (48.7-115.4) |  | Female | 8 | 9.0 | 88.5 | (38.1-174.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 6.5 | 76.7 | (24.7-178.9) |  | Male | 5 | 8.4 | 59.4 | (19.1-138.7) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 8 | 9.6 | 83.1 | (35.8-163.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 98 | 85.3 | 114.9 | (93.2-140.0) |
| Female | 1 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 13.1 | 53.6 | (21.5-110.4) |  | Male | 3 | 5.8 | nc | (nc-nc) |
| Female | 8 | 8.0 | 100.3 | (43.2-197.6) |  | Female | 5 | 3.8 | 130.9 | (42.2-305.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 4 | 2.5 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 9.8 | 122.2 | (63.1-213.4) |  | Male | 1 | 5.7 | nc | (nc-nc) |
| Female | 6 | 7.7 | 78.0 | (28.5-169.7) |  | Female | 22 | 17.1 | 128.7 | (80.6-194.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 8.2 | 73.4 | (26.8-159.8) |  |  |  |  |  |  |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 19 | 21.9 | 86.6 | (52.1-135.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 44.8 | 75.9 | (52.6-106.1) |  | Male | 304 | 324.1 | 93.8 | (83.6-105.0) |
| Female | 43 | 48.0 | 89.7 | (64.9-120.8) |  | Female | 330 | 341.3 | 96.7 | (86.5-107.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

353

# Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 4.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 1.4 | 367.2 | (118.3-856.9) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 5.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 10 | 17.1 | 58.4 | (28.0-107.4) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 12 | 13.3 | 90.5 | (46.7-158.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

354

# Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 23 | 21.6 | 106.4 | (67.4-159.6) |  | Male | 24 | 13.9 | 173.1 | (110.9-257.6) |
| Female | 8 | 7.9 | 101.8 | (43.8-200.6) |  | Female | 20 | 11.0 | 182.6 | (111.5-282.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 3.8 | nc | (nc-nc) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 4 | 3.3 | nc | (nc-nc) |  | Female | 7 | 3.4 | 208.4 | (83.5-429.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 5 | 12.2 | 41.1 | (13.2-95.9) |
| Female | 91 | 84.7 | 107.5 | (86.5-132.0) |  | Female | 10 | 10.5 | 95.5 | (45.7-175.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 9.7 | 112.8 | (56.3-201.9) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 1 | 4.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 23.6 | 114.2 | (75.2-166.1) |  |  |  |  |  |  |
| Female | 22 | 23.8 | 92.6 | (58.0-140.2) |  | Female | 12 | 7.7 | 155.1 | (80.1-271.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 5.8 | 104.1 | (38.0-226.6) |  | Male | 11 | 7.3 | 149.7 | (74.6-267.9) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 8 | 7.6 | 104.7 | (45.1-206.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 70 | 77.3 | 90.5 | (70.6-114.4) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 11.5 | 190.6 | (119.4-288.6) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 14 | 6.8 | 206.8 | (113.0-347.0) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 3.2 | 157.4 | (50.7-367.2) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 8.4 | 95.8 | (41.2-188.7) |  | Male | 8 | 5.2 | 154.1 | (66.4-303.6) |
| Female | 5 | 6.1 | 81.9 | (26.4-191.1) |  | Female | 16 | 15.2 | 105.0 | (60.0-170.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 7.2 | 110.8 | (47.7-218.4) |  |  |  |  |  |  |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 22 | 19.5 | 112.6 | (70.5-170.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 58 | 39.1 | 148.3 | (112.6-191.7) |  | Male | 320 | 285.6 | 112.0 | (100.1-125.0) |
| Female | 46 | 41.1 | 111.9 | (81.9-149.2) |  | Female | 322 | 287.8 | 111.9 | (100.0-124.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

355

# Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 55 | 43.1 | 127.6 | (96.1-166.1) |  | Male | 33 | 27.6 | 119.6 | (82.3-168.0) |
| Female | 22 | 17.1 | 128.3 | (80.4-194.3) |  | Female | 21 | 23.0 | 91.2 | (56.5-139.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 7.8 | 76.6 | (28.0-166.7) |  | Male | 7 | 8.0 | 87.2 | (34.9-179.7) |
| Female | 10 | 7.0 | 142.0 | (68.0-261.1) |  | Female | 7 | 7.2 | 97.8 | (39.2-201.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 29 | 24.3 | 119.2 | (79.8-171.2) |
| Female | 190 | 171.6 | 110.7 | (95.5-127.6) |  | Female | 27 | 22.2 | 121.8 | (80.2-177.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 21 | 18.7 | 112.5 | (69.6-172.0) |
| Female | 7 | 5.9 | 118.2 | (47.4-243.5) |  | Female | 11 | 9.0 | 121.6 | (60.6-217.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 62 | 46.9 | 132.1 | (101.3-169.4) |  |  |  |  |  |  |
| Female | 51 | 52.0 | 98.1 | (73.0-129.0) |  | Female | 20 | 15.9 | 126.1 | (77.0-194.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 11.1 | 108.6 | (56.0-189.7) |  | Male | 17 | 14.4 | 118.4 | (68.9-189.5) |
| Female | 1 | 3.3 | nc | (nc-nc) |  | Female | 20 | 16.8 | 119.3 | (72.8-184.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 124 | 143.3 | 86.5 | (72.0-103.2) |
| Female | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 26 | 22.4 | 116.2 | (75.9-170.2) |  | Male | 10 | 9.9 | 100.7 | (48.2-185.2) |
| Female | 17 | 14.1 | 120.8 | (70.3-193.4) |  | Female | 8 | 6.6 | 121.4 | (52.3-239.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 6.1 | nc | (nc-nc) |  | Male | 7 | 6.0 | 116.5 | (46.7-240.0) |
| Female | 4 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 16.9 | 118.4 | (72.3-182.8) |  | Male | 11 | 10.4 | 106.0 | (52.8-189.7) |
| Female | 17 | 13.4 | 126.9 | (73.9-203.1) |  | Female | 34 | 31.3 | 108.5 | (75.1-151.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 13.9 | 100.7 | (55.0-169.0) |  |  |  |  |  |  |
| Female | 1 | 5.0 | nc | (nc-nc) |  | Female | 41 | 38.5 | 106.6 | (76.5-144.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 97 | 76.8 | 126.2 | (102.4-154.0) |  | Male | 618 | 556.3 | 111.1 | (102.5-120.2) |
| Female | 83 | 86.5 | 95.9 | (76.4-118.9) |  | Female | 670 | 601.2 | 111.4 | (103.2-120.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

356

# Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 176 | 156.5 | 112.4 | (96.4-130.3) |  | Male | 61 | 104.0 | 58.7 | (44.9-75.4) |
| Female | 68 | 61.5 | 110.6 | (85.9-140.2) |  | Female | 53 | 90.9 | 58.3 | (43.7-76.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 28 | 32.3 | 86.8 | (57.6-125.4) |  | Male | 28 | 29.6 | 94.4 | (62.7-136.5) |
| Female | 24 | 28.6 | 84.0 | (53.8-124.9) |  | Female | 25 | 25.9 | 96.5 | (62.4-142.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  | Male | 103 | 93.0 | 110.8 | (90.4-134.4) |
| Female | 559 | 647.6 | 86.3 | (79.3-93.8) |  | Female | 84 | 82.3 | 102.0 | (81.4-126.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 73 | 72.3 | 101.0 | (79.1-126.9) |
| Female | 34 | 24.1 | 141.3 | (97.9-197.5) |  | Female | 38 | 33.8 | 112.3 | (79.5-154.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 154 | 175.3 | 87.8 | (74.5-102.9) |  |  |  |  |  |  |
| Female | 186 | 190.2 | 97.8 | (84.2-112.9) |  | Female | 63 | 60.5 | 104.2 | (80.1-133.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 56 | 41.1 | 136.2 | (102.9-176.8) |  | Male | 48 | 53.0 | 90.5 | (66.7-120.0) |
| Female | 12 | 11.7 | 102.8 | (53.1-179.6) |  | Female | 64 | 60.4 | 105.9 | (81.6-135.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 14 | 16.0 | 87.7 | (47.9-147.2) |  | Male | 522 | 540.4 | 96.6 | (88.5-105.3) |
| Female | 15 | 14.0 | 107.3 | (60.0-177.1) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 91 | 85.4 | 106.5 | (85.8-130.8) |  | Male | 37 | 36.8 | 100.7 | (70.9-138.8) |
| Female | 58 | 52.3 | 110.9 | (84.2-143.3) |  | Female | 32 | 24.1 | 132.5 | (90.6-187.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 18 | 22.7 | 79.2 | (46.9-125.1) |  | Male | 19 | 29.0 | 65.5 | (39.4-102.3) |
| Female | 11 | 7.8 | 141.3 | (70.4-252.8) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 61 | 66.0 | 92.4 | (70.7-118.8) |  | Male | 44 | 42.5 | 103.6 | (75.3-139.1) |
| Female | 53 | 51.6 | 102.6 | (76.9-134.3) |  | Female | 111 | 133.2 | 83.3 | (68.5-100.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 83 | 52.9 | 157.0 | (125.0-194.6) |  |  |  |  |  |  |
| Female | 22 | 18.2 | 120.9 | (75.7-183.0) |  | Female | 159 | 144.6 | 110.0 | (93.5-128.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 333 | 278.5 | 119.6 | (107.1-133.1) |  | Male | 2105 | 2098.1 | 100.3 | (96.1-104.7) |
| Female | 357 | 309.1 | 115.5 | (103.8-128.1) |  | Female | 2195 | 2257.4 | 97.2 | (93.2-101.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

357

# Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 3 | 6.3 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 6.8 | 87.7 | (32.0-190.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 4 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 3.1 | 161.2 | (52.0-376.3) |  | Male | 27 | 23.2 | 116.2 | (76.5-169.0) |
| Female | 0 | 2.8 | nc | (nc-nc) |  | Female | 17 | 20.4 | 83.4 | (48.6-133.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

358

# Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 11.1 | 98.7 | (49.2-176.7) |  | Male | 5 | 7.6 | 65.8 | (21.2-153.6) |
| Female | 3 | 4.3 | nc | (nc-nc) |  | Female | 11 | 6.1 | 179.0 | (89.2-320.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 10 | 6.7 | 148.6 | (71.1-273.3) |
| Female | 53 | 48.1 | 110.2 | (82.6-144.2) |  | Female | 1 | 5.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.8 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 6 | 2.4 | 245.7 | (89.7-534.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 13.0 | 153.6 | (93.8-237.2) |  |  |  |  |  |  |
| Female | 9 | 13.7 | 65.7 | (30.0-124.7) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.2 | 190.2 | (69.5-414.0) |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 56 | 43.0 | 130.3 | (98.4-169.2) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 6.6 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 4.6 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 5 | 8.8 | 57.0 | (18.4-132.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 4 | 10.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 20.4 | 107.8 | (67.5-163.2) |  | Male | 174 | 156.5 | 111.2 | (95.3-129.0) |
| Female | 15 | 21.7 | 69.0 | (38.6-113.8) |  | Female | 145 | 161.1 | 90.0 | (75.9-105.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

359

# Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 52 | 47.3 | 110.0 | (82.2-144.3) |  | Male | 38 | 26.4 | 143.9 | (101.9-197.6) |
| Female | 27 | 17.7 | 152.3 | (100.3-221.6) |  | Female | 45 | 19.6 | 230.1 | (167.8-307.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 6.4 | nc | (nc-nc) |  | Male | 10 | 8.1 | 123.4 | (59.1-227.0) |
| Female | 8 | 6.0 | 132.9 | (57.2-261.8) |  | Female | 8 | 7.2 | 110.6 | (47.6-218.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 28 | 23.3 | 120.0 | (79.7-173.4) |
| Female | 172 | 152.6 | 112.7 | (96.5-130.9) |  | Female | 23 | 21.5 | 107.1 | (67.9-160.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 16.3 | 135.1 | (84.7-204.6) |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 11 | 8.5 | 128.8 | (64.2-230.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 43 | 47.0 | 91.5 | (66.2-123.2) |  |  |  |  |  |  |
| Female | 45 | 51.5 | 87.4 | (63.7-117.0) |  | Female | 9 | 14.4 | 62.5 | (28.5-118.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 19 | 11.0 | 172.1 | (103.5-268.7) |  | Male | 19 | 15.0 | 126.3 | (76.0-197.2) |
| Female | 5 | 3.4 | 148.7 | (47.9-347.0) |  | Female | 13 | 17.4 | 74.5 | (39.6-127.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 2.1 | 234.5 | (75.6-547.2) |  | Male | 166 | 138.6 | 119.8 | (102.3-139.5) |
| Female | 3 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 20.1 | 69.7 | (38.1-116.9) |  | Male | 6 | 10.2 | 58.8 | (21.5-128.0) |
| Female | 11 | 13.2 | 83.1 | (41.4-148.7) |  | Female | 5 | 6.6 | 75.7 | (24.4-176.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 29 | 16.5 | 176.2 | (118.0-253.0) |  | Male | 12 | 7.5 | 159.7 | (82.4-279.0) |
| Female | 17 | 12.5 | 135.8 | (79.1-217.4) |  | Female | 12 | 21.3 | 56.3 | (29.0-98.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 14 | 12.8 | 109.3 | (59.7-183.5) |  |  |  |  |  |  |
| Female | 8 | 4.9 | 162.4 | (69.9-319.9) |  | Female | 31 | 35.4 | 87.5 | (59.5-124.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 92 | 81.5 | 112.9 | (91.0-138.4) |  | Male | 621 | 545.6 | 113.8 | (105.0-123.1) |
| Female | 98 | 88.2 | 111.1 | (90.2-135.3) |  | Female | 611 | 559.3 | 109.2 | (100.7-118.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

360